Chromatin occupancy assessment an AML cell line treated with vehicle control, BETi, MDM2i, or a drug combination (p53-bound profiles)

p53 chromatin occupancy changes in human OCI-AML3 cells treated with DMSO (vehicle control), the BET inhibitor CPI-203, the MDM2 inhibitor Nutlin-3a, or a combination of both drugs, were compared. Method: Genomic DNA from the OCI-AML3 cell line treated for 24 hrs with either DMSO, CPI-203, Nutlin-3a or a combination of both drugs was extracted, p53-bound chromatin was immunoprecipitated, then DNA was sequenced with an Illumina NextSeq 500 sequencer. Sequence reads passing the quality control filters were aligned using Bowtie2 and then analysed with MACS. Overall design: p53-bound chromatin profiles from drug-treated human OCI-AML3 cells were generated, in quadruplicate, using an Illumina NextSeq 500 sequencer.